Table 4. Association of Inflammatory CNS Events With Exposure to Tumor Necrosis Factor Inhibitors.
| Variable | Outcome | Patients and control participants, No. | No. (%) | OR (95% CI) | P value | |
|---|---|---|---|---|---|---|
| Exposed patients | Exposed control participants | |||||
| Primary analysis | ||||||
| All autoimmune diseases | 212 | 64 (60) | 42 (40) | 3.01 (1.55-5.82) | .001 | |
| Secondary analyses stratified by autoimmune disease | ||||||
| RA | Any inflammatory CNS event | 96 | 30 (63) | 16 (33) | 4.82 (1.62-14.36) | .005 |
| Non-RA (AS, P/PA, CD, UC) | Any inflammatory CNS event | 116 | 34 (59) | 26 (45) | 2.13 (0.90-5.05) | .09 |
| Secondary analyses stratified by outcome | ||||||
| All autoimmune diseases | Inflammatory demyelinating CNS events | 112 | 39 (70) | 28 (50) | 3.09 (1.19-8.04) | .02 |
| All autoimmune diseases | Inflammatory nondemyelinating CNS events | 100 | 25 (50) | 14 (28) | 2.97 (1.15-7.65) | .02 |
Abbreviations: AS, ankylosing spondylitis; CD, Crohn disease; CNS, central nervous system; OR, odds ratio; P/PA, psoriasis and psoriatic arthritis; RA, rheumatoid arthritis; UC, ulcerative colitis.